GlassScriptPhysician profile
Hernan A Palermo
NPI 1003851452
$4,680.63
in general payments reported to CMS, 2019-2025
23 companies · $664 in 2025
The $664 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $473 · 2021: $772 · 2022: $614 · 2023: $684 · 2024: $899 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Entertainment: $78.28 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.99 |
| Entertainment | $78.28 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $895.89 | 2019-2022 | |
| Abbvie INC. | $670.05 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $553.32 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $506.63 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $466.51 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $293.42 | 2019-2025 | Rocklatan, Tryptyr, Simbrinza |
| Biotissue Holdings INC. | $213.34 | 2021-2025 | |
| Harrow Eye, LLC | $179.35 | 2024-2025 | Vevye |
| Dompe US, INC. | $172.99 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $129.42 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $112.71 | 2019-2021 | |
| Thea Pharma INC. | $109.41 | 2022-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $79.09 | 2022-2025 | Tyrvaya |
| Optos, INC. | $78.28 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $39.12 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $35.71 | 2019 | |
| Kala Pharmaceuticals, INC. | $33.04 | 2019-2021 | |
| Glaukos Corporation | $29.14 | 2025 | Istent Infinite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.04 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.87 | 2020 | |
| Celularity INC. | $16.70 | 2020 | |
| Astellas Pharma US INC | $15.75 | 2024 | Izervay |
| Sight Sciences, INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Palermo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.